Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics Guidance for Industry

March 10, 2025

Share this page

The accelerated approval pathway is working as intended: delivering better health to those in dire need. Unfortunately, non-oncology rare diseases are nowhere near that milestone and account for just 23% of all products approved using the accelerated approval pathway.

Accelerated Approval

Related Articles

EveryLife Issues Statement on House Energy & Commerce Hearing March 17, 2022
EveryLife Joins Rare Disease Leaders in Call to Strengthen and Protect Accelerated Approval Pathway February 22, 2022
FDA’s Accelerated Approval Pathway: Separating Fact From Fiction October 20, 2021